Article

ISTA acquires rights to 3 ophthalmic compounds

Irvine, CA-ISTA Pharmaceuticals, Irvine, CA, entered into an agreement with AcSentient Inc. under which ISTA will acquire rights to three late-stage ophthalmology compounds.

Related Videos
Related Content
EyePoint Pharmaceuticals announces first patient dosed in global Phase 3 LUGANO clinical trial of Duravyu for wet AMD
October 24th 2024

EyePoint Pharmaceuticals announces first patient dosed in global Phase 3 LUGANO clinical trial of Duravyu for wet AMD

Week in Review - October 5, 2024
October 13th 2024

Week in Review - October 5, 2024

Study estimates glaucoma and vision-affecting glaucoma prevalence by demographic factors
October 23rd 2024

Study estimates glaucoma and vision-affecting glaucoma prevalence by demographic factors

EyePod: AI’s impact on managing ocular surface disease with Peter J. McDonnell, MD, and Laura M. Periman, MD
October 11th 2024

Innovation Series: AI’s impact on managing ocular surface disease with Peter J. McDonnell, MD, and Laura M. Periman, MD

The top 10 takeaways from AAO 2024
October 23rd 2024

The top 10 takeaways from AAO 2024

Real-world evidence on latest retinal disease therapies
October 23rd 2024

Real-world evidence on latest retinal disease therapies

© 2024 MJH Life Sciences

All rights reserved.